Compare
Schrodinger, Inc. vs Arvinas, Inc. vs Arcus Biosciences, Inc. vs Ligand Pharmaceuticals Inc
| Latest fiscal year | Schrodinger, Inc. SDGR | Arvinas, Inc. ARVN | Arcus Biosciences, Inc. RCUS | Ligand Pharmaceuticals Inc LGND |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $255.87M | $262.60M | $247.00M | $268.09M |
| Revenue growth (YoY) | +23.3% | -0.3% | -4.3% | +60.4% |
| Gross margin | 55.7% | n/a | n/a | n/a |
| Operating margin | -65.2% | -45.1% | -156.3% | 15.3% |
| Net margin | -40.4% | -30.8% | -142.9% | 46.4% |
| Net income | -$103.27M | -$80.80M | -$353.00M | $124.45M |
| EPS (Diluted) | -$1.41 | -$1.14 | -$3.29 | $6.13 |
| Operating cash flow | $13.90M | -$273.80M | -$482.00M | $49.36M |
| Free cash flow | $12.46M | -$275.70M | -$484.00M | $48.91M |
| Cash & equivalents | $230.52M | $142.90M | $222.00M | $174.93M |
| Total assets | $726.16M | $717.90M | $1.14B | $1.56B |
| Total liabilities | $362.11M | $284.00M | n/a | $543.42M |
| Shareholders' equity | $364.05M | $433.90M | $631.00M | $1.02B |
| Return on year-end equity | -28.4% | -18.6% | -55.9% | 12.2% |
| Shares outstanding | n/a | 63.50M | 125.30M | 19.77M |
Revenue, most recent five fiscal years
| Fiscal year | Schrodinger, Inc. | Arvinas, Inc. | Arcus Biosciences, Inc. | Ligand Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $255.87M Ended 2025-12-31 | $262.60M Ended 2025-12-31 | $247.00M Ended 2025-12-31 | $268.09M Ended 2025-12-31 |
| 1 year earlier | $207.54M Ended 2024-12-31 | $263.40M Ended 2024-12-31 | $258.00M Ended 2024-12-31 | $167.13M Ended 2024-12-31 |
| 2 years earlier | $216.67M Ended 2023-12-31 | $78.50M Ended 2023-12-31 | $117.00M Ended 2023-12-31 | $131.31M Ended 2023-12-31 |
| 3 years earlier | $180.96M Ended 2022-12-31 | $131.40M Ended 2022-12-31 | $112.00M Ended 2022-12-31 | $196.25M Ended 2022-12-31 |
| 4 years earlier | $137.93M Ended 2021-12-31 | $53.60M Ended 2021-12-31 | $383.00M Ended 2021-12-31 | $241.54M Ended 2021-12-31 |